Loading...
XSTO
SENZA
Market cap18mUSD
Jul 09, Last price  
5.54SEK
1D
0.00%
1Q
6.95%
IPO
-86.08%
Name

SenzaGen AB

Chart & Performance

D1W1MN
XSTO:SENZA chart
P/E
—
P/S
3.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.68%
Rev. gr., 5y
48.76%
Revenues
58m
+0.48%
1,624,0001,748,000498,0001,153,0001,997,0002,724,0007,958,00015,422,00041,770,00049,870,00057,695,00057,974,000
Net income
-12m
L-35.09%
262,000-2,857,000-8,942,000-12,994,000-16,090,000-50,237,000-27,315,000-31,346,000-24,912,000-22,097,000-17,850,000-11,587,000
CFO
-7m
L-24.48%
1,043,000-6,281,000-9,692,000-11,646,000-23,212,000-31,081,000-29,376,000-20,980,000-16,071,000-16,453,000-9,330,000-7,046,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SenzaGen AB specializes in pioneering, conducting, and commercializing animal-free methods to evaluate the allergic potential of various substances. Their product portfolio encompasses several in vitro tests: GARDskin identifies potential chemical skin sensitizers; GARDpotency, an enhancement to GARDskin, categorizes their strength; GARDskin Dose-response delivers precise quantitative assessment of skin sensitizing potency; and GARDair detects chemical respiratory sensitizers. They also offer GARDskin medical device for assessing skin sensitization caused by medical equipment and solid materials. Furthermore, the company provides services for irritation and corrosion analysis. SenzaGen distributes its solutions through a network of licensed partners and distributors. The firm also collaborates with the Research Institute for Fragrance Materials to develop novel photosensitization tests. Founded in 2010, the company's headquarters are located in Lund, Sweden.
URL
https://senzagen.com/
IPO date
Sep 21, 2017
Employees
35
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT